Data edition of
Residue An evidence-graded reference for peptide science

BPC-157 vs TB-500

C BPC-157 Proposed: VEGFR2 and Akt–eNOS (nitric oxide) signaling, angiogenesis; not a defined receptor agonist Not FDA-approved · FDA compounding nomination withdrawn D TB-500 Fragment (residues 17–23) of thymosin β4, the region linked to actin binding Not FDA-approved · FDA compounding nomination withdrawn

Residue Editorial Team · updated

In brief

Both are research peptides linked to tissue repair; neither is FDA-approved1FDACertain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. FDA, content current as of 04/22/2026.. BPC-157's evidence is mostly animal: 35 of 36 orthopedic studies in a 2025 systematic review were preclinical2PubMedEmerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. Vasireddi N et al. HSS J. 2025.. TB-500 is a seven-residue thymosin β4 fragment3PubMedSynthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Esposito S et al. Drug Test Anal. 2012.; trials tested the full protein, mainly as eye drops4PubMedThymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model. Sosne G & Ousler GW Clin Ophthalmol. 2015., but FDA has identified no human exposure data for the fragment1.

How do BPC-157 and TB-500 compare at a glance?

Table 1. BPC-157 and TB-500 on the dimensions that matter most; every entry is cited.
DimensionBPC-157TB-500
What it isSynthetic 15-residue peptide originally isolated from gastric juice5PubMedRegeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. McGuire FP et al. Curr Rev Musculoskelet Med. 2025.Ac-LKKTETQ, thymosin β4 residues 17–233
Proposed mechanismVEGFR2 and Akt–eNOS signaling, angiogenesis5Region linked to actin binding, cell migration, wound healing6PubMedDoping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry. Ho EN et al. J Chromatogr A. 2012.
Human dataThree small uncontrolled pilots5None for the fragment; phase 2–3 for full thymosin β44,7PubMedThymosin beta 4 and the eye: the journey from bench to bedside. Sosne G Expert Opin Biol Ther. 2018.
Half-lifeUnder 30 minutes2Not established in humans
Registered studiesPhase 2 hamstring trial recruiting8TrialBPC 157 for Acute Hamstring Muscle Strain Repair. Hudson Biotech · PHASE2 · recruiting.Phase 1/2 fragment study recruiting9TrialTB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD. Hudson Biotech · PHASE1/PHASE2 · recruiting.
FDAWithdrawn nomination; insufficient safety information1Withdrawn nomination; no human exposure data identified1
Evidence gradeCD

Written by Residue Editorial Team

Reviewed by Residue Editorial Team · source-by-source check,

First published

Last updated

Registry data · How we grade · Markdown + sources

Figure 1. Size of the research record, from PubMed and ClinicalTrials.gov at the data edition. Bars are scaled to the larger value in each row; volume is not quality.
PubMed records 225 1,157
Trial publications 0 9
Registered studies 4 20
Phase 3 studies 0 5

BPC-157 TB-500

Where do they come from?

BPC-157 ("body protection compound") is a synthetic 15-amino-acid peptide originally isolated from gastric juice5. TB-500 began as a veterinary preparation; its key ingredient is the seven-residue LKKTETQ segment of thymosin β4 with an N-terminal acetyl group6, which mass spectrometry confirmed in a TB-500 product3.

How are they thought to work?

BPC-157 is not a defined receptor agonist. Reviews describe signaling through VEGFR2 and the Akt–eNOS (nitric oxide) pathway and promotion of angiogenesis, largely from animal and cell studies5. For TB-500, the rationale is that residues 17–23 are the active site within thymosin β4 for actin binding, cell migration and wound healing6.

What does the human evidence show?

BPC-157. A 2025 systematic review screened 544 articles and included 36 orthopedic studies: 35 preclinical and 1 clinical. It found no clinical safety data2. A narrative review counted three human pilot reports — knee pain, interstitial cystitis and an intravenous safety and pharmacokinetics study — none large or controlled5.

TB-500. We found no human outcome study of the fragment; its human-relevant literature is anti-doping detection3,6. Full-length thymosin β4 has more: in a phase 2 dry-eye trial (72 subjects), neither primary endpoint was met, though several secondary endpoints improved4, and eye-drop phase 3 programs followed7. Those results do not transfer automatically to a seven-residue fragment.

Are they FDA-approved?

Neither is FDA-approved. FDA lists BPC-157 and the LKKTETQ fragment among withdrawn compounding nominations; for the fragment it states it has not identified any human exposure data1.

Can you take BPC-157 and TB-500 together?

One retrospective phone survey reported 16 knee-pain patients who received intra-articular BPC-157 alone or with thymosin β4; 14 reported relief, without standardized outcome tools10PubMedIntra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Lee E & Padgett B Altern Ther Health Med. 2021.. Neither peptide is FDA-approved for compounding1.

Two identical glass beakers, one holding pale amber liquid and one clear, standing either side of a brass balance

Why do they get these evidence grades?

C BPC-157
Three small, uncontrolled human pilot reports exist; no randomized controlled human trial has been published. Nearly all evidence is preclinical. Grade C: Limited / early human data.
D TB-500
No human data for the LKKTETQ fragment itself. The parent protein, thymosin β4, has phase 2–3 trials (mainly eye drops) — graded separately below. Grade D: Preclinical only.

Questions readers ask

Is BPC-157 or TB-500 better for healing?

There is no comparative human evidence. BPC-157's orthopedic evidence is 35 preclinical studies and 1 clinical study2; the TB-500 fragment has no published human outcome study, and the trials that exist test full-length thymosin β44.

Have BPC-157 and TB-500 been studied together?

Only in a retrospective phone survey: 16 knee-pain patients received intra-articular BPC-157 alone or with thymosin β4, and 14 reported relief, without standardized outcome tools10.

Can you take BPC-157 and TB-500 together?

One retrospective phone survey reported 16 knee-pain patients who received intra-articular BPC-157 alone or with thymosin β4; 14 reported relief, without standardized outcome tools10. Neither peptide is FDA-approved1.

What are the side effects of BPC-157 vs TB-500?

Published human safety data are sparse for both. A 2025 orthopedic review of BPC-157 found no clinical safety dataset2; FDA states it lacks human exposure data for the TB-500 fragment1.

References

Every source below was retrieved from its official API or page and cached on the data-edition date. Numbers match the margin notes.

  1. 1 FDA Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. FDA, content current as of 04/22/2026.
  2. 2 PubMed Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J 2025. PMID 40756949; doi:10.1177/15563316251355551.
  3. 3 PubMed Esposito S, Deventer K, Goeman J, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal 2012. PMID 22962027; doi:10.1002/dta.1402.
  4. 4 PubMed Sosne G, Ousler GW. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model. Clin Ophthalmol 2015. PMID 26056426; doi:10.2147/OPTH.S80954.
  5. 5 PubMed McGuire FP, Martinez R, Lenz A, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med 2025. PMID 40789979; doi:10.1007/s12178-025-09990-7.
  6. 6 PubMed Ho EN, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A 2012. PMID 23084823; doi:10.1016/j.chroma.2012.09.043.
  7. 7 PubMed Sosne G. Thymosin beta 4 and the eye: the journey from bench to bedside. Expert Opin Biol Ther 2018. PMID 30063853; doi:10.1080/14712598.2018.1486818.
  8. 8 ClinicalTrials.gov BPC 157 for Acute Hamstring Muscle Strain Repair. Hudson Biotech · PHASE2 · recruiting.
  9. 9 ClinicalTrials.gov TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD. Hudson Biotech · PHASE1/PHASE2 · recruiting.
  10. 10 PubMed Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med 2021. PMID 34324435.